Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3
Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from the Institut Pasteur
Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine
Intravacc launches hybrid business model to drive innovation and growth
Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China
Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine
Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine
Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer
Intravacc announces formation of Scientific Advisory Board
Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement
